On October 8, 2026, the clinical trial registry listed an update for a study involving metreleptin, a form of leptin. The trial, titled "Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy," is registered under identifier NCT02262806. It is a Phase 2 study. According to the registry, the trial status is active, not recruiting. This status indicates that the study is ongoing for previously enrolled participants but is not currently accepting new participants. The trial focuses on compassionate use of metreleptin in people with partial lipodystrophy who have been previously treated. No results or outcome data were included in this update. The event reflects only a status and date change in the trial record. Readers interested in the broader context of metreleptin and its approved uses can consult the compound overview for additional background.
Metreleptin Trial for Partial Lipodystrophy Now Active, Not Recruiting
Source: https://clinicaltrials.gov/study/NCT02262806